FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2534068643> ?p ?o ?g. }

• W2534068643 endingPage "240A" @default.
• W2534068643 startingPage "240A" @default.
• W2534068643 abstract "SESSION TITLE: Fellow Case Report Poster - Critical Care I SESSION TYPE: Affiliate Case Report Poster PRESENTED ON: Tuesday, October 25, 2016 at 01:30 PM - 02:30 PM INTRODUCTION: K2 is a new synthetic cannabinoid engineered to resemble marijuana and to reproduce its effects. With a potency 100 times that of marijuana, it has well described neuropsychological but less predictable physiologic manifestations when compared to marijuana. We present a case of a patient with altered sensorium and findings of global cerebral edema after K2 use. CASE PRESENTATION: A 37-year-old man was brought to our Emergency Department (ED) after being found unresponsive. EMS noted fixed-dilated pupils and SpO2 40%. He received naloxone without response and was intubated in the field. Neurologic examination in the ED showed 5mm non-reactive pupils. Corneal, Doll’s eye and gag reflexes were all absent. He exhibited decerebrate posturing with stimulation and intermittent rhythmic flexor motions in the upper extremities coupled with left gaze deviation. Plantar reflexes were downward. He was loaded with levetiracetam and was transferred to the medical intensive care unit. Laboratory tests were unremarkable including acetaminophen, salicylate, and alcohol levels. Urine drug screen was positive for cannabinoids. CT brain revealed global cerebral edema with grey-white matter indifferentiation (image1) consistent with anoxic brain injury. He was treated with hypertonic saline (3%). Two days later, he awakened, was interactive but combative. Two hours after his extubation, he was ambulatory and admitted to marijuana and K2 use. DISCUSSION: The toxicity and adverse effects of the synthetic cannabinoids are unpredictable, potentially life threatening and underreported in literature. They vary widely depending on the specific chemical compound used during their synthesis. Patients usually present with violent behavioral manifestations, seizures and coma. K2 use is also associated with myocardial infarction, strokes, respiratory failure and kidney injury. As there is currently no available test and users underreport it, intensivists need to keep a high index of suspicion in patients at risk. CONCLUSIONS: While altered mental status is a common presentation in K2 users, this is the first reported case of reversible diffuse cerebral edema and its associated neurologic findings. Our case illustrates the degree of neurologic impairment, which may occur with K2 use and aims to raise awareness among intensivists about this emerging public health threat. Reference #1: Tait RJ et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.Clin Toxicol 2016;15;54:1-13 DISCLOSURE: The following authors have nothing to disclose: Ismini Kourouni, Stefania Pirrotta, Raymonde Jean, Keith Rose, Joseph Mathew No Product/Research Disclosure Information" @default.
• W2534068643 created "2016-10-28" @default.
• W2534068643 creator A5024797974 @default.
• W2534068643 creator A5036851205 @default.
• W2534068643 creator A5057429038 @default.
• W2534068643 creator A5074153736 @default.
• W2534068643 creator A5086344645 @default.
• W2534068643 date "2016-10-01" @default.
• W2534068643 modified "2023-09-25" @default.
• W2534068643 title "K2 Synthetic Cannabinoid Causing Reversible Global Cerebral Edema: A Case Report" @default.
• W2534068643 doi "https://doi.org/10.1016/j.chest.2016.08.253" @default.
• W2534068643 hasPublicationYear "2016" @default.
• W2534068643 type Work @default.
• W2534068643 sameAs 2534068643 @default.
• W2534068643 citedByCount "1" @default.
• W2534068643 countsByYear W25340686432020 @default.
• W2534068643 crossrefType "journal-article" @default.
• W2534068643 hasAuthorship W2534068643A5024797974 @default.
• W2534068643 hasAuthorship W2534068643A5036851205 @default.
• W2534068643 hasAuthorship W2534068643A5057429038 @default.
• W2534068643 hasAuthorship W2534068643A5074153736 @default.
• W2534068643 hasAuthorship W2534068643A5086344645 @default.
• W2534068643 hasBestOaLocation W25340686431 @default.
• W2534068643 hasConcept C118552586 @default.
• W2534068643 hasConcept C2780724011 @default.
• W2534068643 hasConcept C3017567848 @default.
• W2534068643 hasConcept C42219234 @default.
• W2534068643 hasConcept C71924100 @default.
• W2534068643 hasConceptScore W2534068643C118552586 @default.
• W2534068643 hasConceptScore W2534068643C2780724011 @default.
• W2534068643 hasConceptScore W2534068643C3017567848 @default.
• W2534068643 hasConceptScore W2534068643C42219234 @default.
• W2534068643 hasConceptScore W2534068643C71924100 @default.
• W2534068643 hasIssue "4" @default.
• W2534068643 hasLocation W25340686431 @default.
• W2534068643 hasOpenAccess W2534068643 @default.
• W2534068643 hasPrimaryLocation W25340686431 @default.
• W2534068643 hasRelatedWork W1533727747 @default.
• W2534068643 hasRelatedWork W2026095104 @default.
• W2534068643 hasRelatedWork W2510700473 @default.
• W2534068643 hasRelatedWork W2549135832 @default.
• W2534068643 hasRelatedWork W2979880696 @default.
• W2534068643 hasRelatedWork W2980093723 @default.
• W2534068643 hasRelatedWork W3005450714 @default.
• W2534068643 hasRelatedWork W3154944956 @default.
• W2534068643 hasRelatedWork W4232888950 @default.
• W2534068643 hasRelatedWork W4238308949 @default.
• W2534068643 hasVolume "150" @default.
• W2534068643 isParatext "false" @default.
• W2534068643 isRetracted "false" @default.
• W2534068643 magId "2534068643" @default.
• W2534068643 workType "article" @default.